iPSC Differentiated Microglia
Applied StemCell offers high-quality iPSC-derived, cryopreserved microglia cells that have been differentiated using a proprietary, integration-free method. The differentiation mimics the in vivo erythromyeloid induction and activation pathway for the development of microglia in the brain to generate physiologically relevant cell lines. These microglia-like cells have been derived from a well-characterized control human iPSC line (ASE-9211), and express microglial-specific markers, P2RY12 and TMEM119 as well as macrophage markers. These are functionally active, high purity (>90%) microglial cells that are ideal as controls for disease modeling, drug screening and co-culture modeling. Also, included with the microglia we also provide proprietary media to ensure robust microglial cultures.
We also provide Hematopoietic Progenitor Cells from the first stage of microglia differentiation.
No, the iPSC-derived microglia cannot be passaged as they do not proliferate. Though, the floating microglia can be re-seeded onto a new plate or cryopreserved up to 1-2 times, we do not have functionality data from these re-seeded cells.
Yes, the optimized media provided for maintaining the microglia is a serum-free media.
This line was differentiated using a proprietary cytokine-based differentiation protocol.
iPSC-derived Microglia (ASE-9601) from Control iPSC Line ASE-9211
Figure 1. Cryopreserved iPSC-derived microglia (iMGLs; ASE-9601). Cryopreserved iMGLs differentiated from Applied StemCell’s control “master” iPSC line, ASE-9211 were recovered in microglia culture media. The cells were fixed the next day and stained with microglial-specific markers, P2RY12+, TMEM119, IBA1, CX3CR1, TREM2 (top row). Bottom row shows the co-localization of the biomarkers with the nuclear counterstain, DAPI.
Microglia are the primary immune cells (macrophages) in the central nervous system (CNS) and they play a crucial role in maintaining neuronal homeostasis and synaptic plasticity for normal brain development and neuronal function, and inflammatory responses. They have also been implicated in the pathogenesis of several neurological disorders such as Alzheimer’s disease and Parkinson’s disease. The differentiation of iPSCs to microglia provide a steady source of primary microglia-like cells without the sourcing issues associated with primary microglia. These cells are an excellent physiologically relevant research model to study immune response mechanisms in the brain, neuronal function, and for disease modeling.
Applied StemCell has developed an efficient cytokine-based method to differentiate high-quality microglia cells from human iPSCs (iMGLs), which recapitulate the phenotype and functional parameters of primary microglia and in vivo microglial cells. Our proprietary erythromyeloid induction protocol mimics the in vivo activation pathway for the development of microglia in the brain from hematopoietic stem cells.
The iMGLs were derived through directed differentiation from an integration-free, control human iPSC line (ASE-9211). These high-purity (≥90%) cells express microglial-specific markers TMEM119, and P2Ry12+ (also referred to as P2Y12+) as well as IBA1, CX3CR1+, and TREM2+ (Figure 1). The cells are provided as fully-differentiated, cryopreserved cells that you can readily recover and culture for your experiments. The iMGLs are functionally viable for 7 days after recovery.
To harness the full potential of our iMGLs, we also provide optimized, serum-free Microglia Culture Media (ASE-9601MM) that supports robust maintenance and functionality of the iMGLs in culture.